Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration

Cancer Research

Volumn 70, Issue 20, 2010, Pages 8187-8198

  Fry, Jessica L ^a   Toker, Alex ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM9 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN;

ADAM PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CROSS REACTIONS; DISEASE PROGRESSION; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOBLOTTING; ISOENZYMES; MEMBRANE PROTEINS; MUTATION; RNA, SMALL INTERFERING; SEQUENCE DELETION; TRANSFECTION;

EID: 78049244413     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4231     Document Type: Article

References (48)

1. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47. (Pubitemid 36818244)
2. Zigrino P, Loffek S, Mauch C. Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie 2005;87:321-8. (Pubitemid 40387611)
3. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8. (Pubitemid 27446075)
4. Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001;154:1069-79. (Pubitemid 34286185)
5. Fowlkes JL, Thrailkill KM, Serra DM, Suzuki K, Nagase H. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res 1995;6:255-63.
6. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996;271:10079-86.
7. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008;8:929-41.
8. Mizgerd JP, Spieker MR, Doerschuk CM. Early response cytokines and innate immunity: essential roles for TNF receptor 1 and type I IL-1 receptor during Escherichia coli pneumonia in mice. J Immunol 2001;166:4042-8.
9. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76. (Pubitemid 30070982)
10. Iba K, Albrechtsen R, Gilpin B, et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading. J Cell Biol 2000;149:1143-56.
11. Gaultier A, Cousin H, Darribere T, Alfandari D. ADAM13 disintegrin and cysteine-rich domains bind to the second heparin-binding domain of fibronectin. J Biol Chem 2002;277:23336-44. (Pubitemid 34952164)
12. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7-30.
13. Kveiborg M, Frohlich C, Albrechtsen R, et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res 2005;65:4754-61. (Pubitemid 40740812)
14. Pories SE, Zurakowski D, Roy R, et al. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2008;17:1034-42.
15. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323-30. (Pubitemid 40017878)
16. Trochon-Joseph V, Martel-Renoir D, Mir LM, et al. Evidence of anti-angiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res 2004;64:2062-9. (Pubitemid 38339454)
17. Beck V, Herold H, Benge A, et al. ADAM15 decreases integrin αvβ3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int J Biochem Cell Biol 2005;37:590-603. (Pubitemid 40022936)
18. Kleino I, Ortiz RM, Huovila AP. ADAM15 gene structure and differential alternative exon use in human tissues. BMC Mol Biol 2007;8:90. (Pubitemid 350286458)
19. Izumi Y, Hirata M, Hasuwa H, et al. A metalloprotease-disintegrin, MDC9/meltrin-γ/ADAM9 and PKCδ are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 1998;17:7260-72.
20. Ongusaha PP, Kwak JC, Zwible AJ, et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 2004;64:5283-90.
21. Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, Zolkiewska A. Proteolytic processing of delta-like 1 by ADAM proteases. J Biol Chem 2007;282:436-44. (Pubitemid 47076599)
22. Parkin E, Harris B. A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10. J Neurochem 2009;108:1464-79.
23. Tousseyn T, Thathiah A, Jorissen E, et al. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the γ-secretase. J Biol Chem 2009;284:11738-47.
24. Mahimkar RM, Visaya O, Pollock AS, Lovett DH. The disintegrin domain of ADAM9: a ligand for multiple β1 renal integrins. Biochem J 2005;385:461-8. (Pubitemid 40165079)
25. Zigrino P, Steiger J, Fox JW, et al. Role of ADAM-9 disintegrincysteine- rich domains in human keratinocyte migration. J Biol Chem 2007;282:30785-93. (Pubitemid 350035232)
26. Mazzocca A, Coppari R, De Franco R, et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res 2005;65:4728-38. (Pubitemid 40740809)
27. Karadag A, Zhou M, Croucher PI. ADAM-9 (MDC-9/meltrin-γ), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the α(v)β5 integrin. Blood 2006;107:3271-8.
28. Maschler S, Wirl G, Spring H, et al. Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 2005;24:2032-41. (Pubitemid 40516196)
29. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Rocken C. Increased expression of ADAMfamily members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2005;131:41-8.
30. O'Shea C, McKie N, Buggy Y, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 2003;105:754-61. (Pubitemid 36706097)
31. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27. (Pubitemid 44854747)
32. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006;124:1283-98.
33. Flanagan L, Van Weelden K, Ammerman C, Ethier SP, Welsh J. SUM-159PT cells: a novel estrogen independent human breast cancer model system. Breast Cancer Res Treat 1999;58:193-204. (Pubitemid 30113871)
34. Wulf GM, Ryo A, Wulf GG, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001;20:3459-72. (Pubitemid 32634353)
35. Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP. Critical function for ADAM9 in mouse prostate cancer. Cancer Res 2005;65:9312-9. (Pubitemid 41507998)
36. Lee EC, Lotz MM, Steele GD, Jr., Mercurio AM. The integrin α6β4 is a laminin receptor. J Cell Biol 1992;117:671-8.
37. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41. (Pubitemid 44854748)
38. Weskamp G, Cai H, Brodie TA, et al. Mice lacking the metalloprotease- disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol Cell Biol 2002;22:1537-44. (Pubitemid 34150789)
39. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212-7.
40. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, et al. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 2005;11:7311-21. (Pubitemid 41507689)
41. Zigrino P, Mauch C, Fox JW, Nischt R. Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer 2005;116:853-9. (Pubitemid 41209190)
42. Shigemura K, Sung SY, Kubo H, et al. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 2007;67:722-31. (Pubitemid 46709441)
43. Sung SY, Kubo H, Shigemura K, et al. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res 2006;66:9519-26. (Pubitemid 44623650)
44. Simpson KJ, Selfors LM, Bui J, et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol 2008;10:1027-38.
45. Nath D, Slocombe PM, Webster A, Stephens PE, Docherty AJ, Murphy G. Meltrin γ (ADAM-9) mediates cellular adhesion through α(6)β(1) integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci 2000;113:2319-28.
46. Cominetti MR, Martin AC, Ribeiro JU, et al. Inhibition of platelets and tumor cell adhesion by the disintegrin domain of human ADAM9 to collagen I under dynamic flow conditions. Biochimie 2009;91:1045-52.
47. Thodeti CK, Albrechtsen R, Grauslund M, et al. ADAM12/syndecan-4 signaling promotes β1 integrin-dependent cell spreading through protein kinase Cα and RhoA. J Biol Chem 2003;278:9576-84. (Pubitemid 36800452)
48. Hirao T, Nanba D, Tanaka M, et al. Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res 2006;312:331-9 (Pubitemid 41814842)